A lot of mediators are underutilizing LinkedIn, even though it can be an incredibly effective tool for visibility, relationship building and business development.
Some have profiles that haven’t been updated in years. Others occasionally share a speaking engagement or article, but there’s no real consistency or visibility strategy behind it. And many still assume LinkedIn
Here’s my Above the Law post on Zach Abramowitz’s keynote at ILTA’s Evolve conferance. The keynote lived up to its title: Most Law Firms Are Doing AI Wrong. Here’s How to Do It Right.
His argument is that the failures in GenAI adoption from ineffective training to analysis paralysis to hallucination panic, all trace back
Quick Hits
Violins made by Antonio Stradivari (called “Strads”) in the late-Seventeenth and early-Eighteenth centuries are widely considered the best ever made. Yet for more than three centuries, musicians, collectors, scientists, and instrument makers (luthiers) have tried to determine why Strads stand in a class of their own.There are many theories why Strads are unique. Maybe the
The Colorado AI Act (SB24-205) is effectively frozen just weeks before its June 30, 2026 effective date, following a stay in enforcement of the law by a Magistrate Judge in the District of Colorado on April 27, 2026.
Background
By way of background, on April 9, xAI filed suit in federal court seeking to enjoin
AbbVie Submits Regulatory Application to FDA for Subcutaneous SKYRIZI
On April 27, 2026, AbbVie announced that it has submitted a regulatory application to the FDA seeking approval for SKYRIZI (risankizumab-rzaa) for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn’s disease. AbbVie states that its application is supported by positive data
Evan Bundschuh
Burkhard Fassbach
In the following guest post, Evan Bundschuh and Burkhard Fassbach share and analyze their research into the AI-related Form 10-K disclosures of 26 U.S.-listed public companies, in order to assess the level and significance of public companies’ disclosure statements pertaining to artificial intelligence. Evan is Vice President at GB&A, a retail insurance brokerage in New York, and Burkhard is a D&O lawyer in private practice in Germany. My thanks to Evan and Burkhard for allowing us to publish their article on this site. Here is their article.
Bexis recently attended the Spring Conference of the Product Liability Advisory Council (“PLAC”). PLAC meetings are usually good for new blogpost ideas, and this one was no exception. Today’s idea comes from an unusual source, though – the final day’s ethics presentation. That presentation was about artificial intelligence, mostly in the mass tort context. One
The NewYorkTimes.con reported that “The trial of the artificial intelligence age, a legal battle between Elon Musk and OpenAI, is set to begin Monday in a courtroom in Oakland, Calif.” The April 27, 2026 article entitled “The OpenAI trial is set to start” (https://www.nytimes.com/2026/04/27/business/dealbook/musk-altman-ai-trial.html?smid=nytcore-ios-share) included these comments:
But while much of the attention is on the juicy